| 30/09/22 | 10:30:07 | 30 Sept 2022 | | Board Committee Changes |
| 27/09/22 | 07:05:05 | 27 Sept 2022 | | Koselugo approved in Japan for NF1 |
| 27/09/22 | 07:00:07 | 27 Sept 2022 | | Tezspire approved in Japan for severe asthma |
| 23/09/22 | 07:00:08 | 23 Sept 2022 | | Ultomiris approved in EU for gMG |
| 22/09/22 | 07:00:14 | 22 Sept 2022 | | Lynparza approved in China for ovarian cancer |
| 21/09/22 | 07:00:06 | 21 Sept 2022 | | Tezspire approved in the EU for severe asthma |
| 20/09/22 | 07:00:13 | 20 Sept 2022 | | Evusheld approved in EU for COVID-19 treatment |
| 16/09/22 | 07:10:01 | 16 Sept 2022 | | Danicopan Phase III trial met primary endpoint |
| 16/09/22 | 07:05:00 | 16 Sept 2022 | | Evusheld positive CHMP opinion in EU |
| 16/09/22 | 07:00:04 | 16 Sept 2022 | | Nirsevimab recommended for approval in EU by CHMP |
| 05/09/22 | 07:05:05 | 5 Sept 2022 | | Forxiga approved in China for CKD |
| 05/09/22 | 07:00:07 | 5 Sept 2022 | | Imfinzi approved in US for biliary tract cancer |
| 01/09/22 | 15:00:04 | 1 Sept 2022 | | Total Voting Rights |
| 30/08/22 | 13:00:01 | 30 Aug 2022 | | Evusheld approved for COVID-19 in Japan |
| 30/08/22 | 07:01:04 | 30 Aug 2022 | | Farxiga shows CV mortality benefit across EF range |
| 30/08/22 | 07:00:13 | 30 Aug 2022 | | Farxiga reduced risk of CV death or worsening HF |
| 25/08/22 | 07:10:01 | 25 Aug 2022 | | Ultomiris approved in Japan for gMG |
| 25/08/22 | 07:05:00 | 25 Aug 2022 | | Tagrisso approved in Japan for early lung cancer |
| 25/08/22 | 07:00:03 | 25 Aug 2022 | | Lynparza approved in Japan for early breast cancer |
| 16/08/22 | 07:00:11 | 16 Aug 2022 | | Lynparza granted FDA priority review for PROpel |
| 15/08/22 | 07:00:06 | 15 Aug 2022 | | Enhertu improved PFS in mBC in DESTINY-Breast02 |
| 12/08/22 | 07:00:09 | 12 Aug 2022 | | Enhertu approved in US for HER2-mutant NSCLC |
| 11/08/22 | 07:00:12 | 11 Aug 2022 | | Acquisition of TeneoTwo completed |
| 08/08/22 | 07:10:05 | 8 Aug 2022 | | Enhertu approved in the US for HER2-low mBC |
| 04/08/22 | 07:00:07 | 4 Aug 2022 | | Lynparza approved in EU for early breast cancer |
| 01/08/22 | 17:00:02 | 1 Aug 2022 | | Director/PDMR Shareholding |
| 01/08/22 | 15:05:01 | 1 Aug 2022 | | Director/PDMR Shareholding |
| 01/08/22 | 15:00:01 | 1 Aug 2022 | | Total Voting Rights |
| 29/07/22 | 07:01:05 | 29 Jul 2022 | | Chair succession |
| 29/07/22 | 07:00:11 | 29 Jul 2022 | | Half-year Report |
| 25/07/22 | 07:10:05 | 25 Jul 2022 | | Tezspire recommended for EU approval in asthma |
| 25/07/22 | 07:05:06 | 25 Jul 2022 | | Ultomiris recommended for EU approval for gMG |
| 25/07/22 | 07:00:06 | 25 Jul 2022 | | Enhertu granted Priority Review for HER2-low mBC |
| 19/07/22 | 07:00:07 | 19 Jul 2022 | | Enhertu approved in EU for HER2-positive mBC |
| 05/07/22 | 07:00:04 | 5 Jul 2022 | | AstraZeneca to acquire TeneoTwo and T cell engager |
| 01/07/22 | 15:00:12 | 1 Jul 2022 | | Total Voting Rights |
| 30/06/22 | 07:00:08 | 30 Jun 2022 | | Imfinzi improved pCR in resectable lung cancer |
| 27/06/22 | 07:05:04 | 27 Jun 2022 | | Enhertu recommended for breast cancer EU approval |
| 27/06/22 | 07:00:08 | 27 Jun 2022 | | Lynparza recommended in EU for early breast cancer |
| 21/06/22 | 07:00:06 | 21 Jun 2022 | | Eplontersen Ph III trial met co-primary endpoints |
| 06/06/22 | 07:00:09 | 6 Jun 2022 | | Enhertu efficacy results in HER2-low breast cancer |
| 01/06/22 | 15:00:00 | 1 Jun 2022 | | Block listing Interim Review |
| 01/06/22 | 15:00:00 | 1 Jun 2022 | | Total Voting Rights |
| 20/05/22 | 16:00:04 | 20 May 2022 | | Director/PDMR Shareholding |
| 09/05/22 | 13:00:01 | 9 May 2022 | | Appointment of joint corporate brokers |
| 06/05/22 | 16:00:01 | 6 May 2022 | | Director/PDMR Shareholding |
| 05/05/22 | 07:10:02 | 5 May 2022 | | Enhertu approved in US for 2L HER2+ breast cancer |
| 05/05/22 | 07:05:01 | 5 May 2022 | | Farxiga HFpEF Phase III trial met primary endpoint |
| 05/05/22 | 07:00:04 | 5 May 2022 | | Ultomiris NMOSD Ph. III trial met primary endpoint |
| 04/05/22 | 07:00:04 | 4 May 2022 | | Imfinzi combo granted Priority Review for BTC |
